Skip to search formSkip to main contentSkip to account menu

PMitCEBO

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and…
BACKGROUND Advanced age is an independent poor prognostic factor of diffuse large B-cell lymphoma. PMitCEBO is an alternative to… 
2015
2015
Diffuse large B-cell lymphoma response to Rituximab-PmitCEBO regimen is not predicted by FcγRIIIa158 polymorphism.
1,2,4Cristina Bagacean, 3Naelle Lombion, 3Adrian Tempescul, 3Jean-Christophe Ianotto, 3Christian Berthou, 4Yves Renaudineau, 1… 
2008
2008
randomized trial of PAdriaCEBO versus PMitCEBO patients older than 60 with high-grade lymphoma: results of a BNLI Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for
http://bloodjournal.hematologylibrary.org/cgi/content/full/97/10/2991 Updated information and services can be found at: (4075… 
2005
2005
Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA…
6529 Background: The addition of rituximab (R) to 6 cycles of CHOP-like regimens in the MInT trial significantly improved overall… 
1997
1997
Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma.
A chemotherapy schedule comprising mitozantrone, cyclophosphamide, etoposide alternating weekly with bleomycin and vincristine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)